

**Supplementary Table 1.** Baseline characteristics of the patients without shockable initial rhythm

| Variable                                  | Delayed nutrition support<br>(n=19) | Early nutrition support<br>(n=16) | Total<br>(n=35) | P-value |
|---|-------------------------------------|-----------------------------------|-----------------|---------|
| Age (yr)                                  | 67.9±14.8                           | 68.5±16.4                         | 68.2±15.3       | 0.912   |
| Male                                      | 7 (36.8)                            | 6 (35.3)                          | 13 (36.1)       | 0.923   |
| Body mass index (kg/m <sup>2</sup> )      | 22.4±3.5                            | 22.2±4.8                          | 22.3±4.1        | 0.872   |
| Weight (kg)                               | 62.0±11.3                           | 57.7±11.7                         | 59.9±11.5       | 0.282   |
| Height (cm)                               | 166.2±9.2                           | 161.6±6.7                         | 163.9±8.3       | 0.102   |
| Comorbidity                               |                                     |                                   |                 |         |
| Hypertension                              | 9 (47.4)                            | 7 (41.1)                          | 16 (44.4)       | 0.709   |
| Diabetes                                  | 3 (15.8)                            | 7 (41.2)                          | 10 (27.8)       | 0.139   |
| CKD                                       | 2 (10.5)                            | 6 (35.3)                          | 8 (22.2)        | 0.114   |
| Malignancy                                | 1 (5.3)                             | 2 (11.8)                          | 3 (8.3)         | 0.593   |
| ACS                                       | 2 (10.5)                            | 0                                 | 2 (5.6)         | 0.487   |
| COPD                                      | 0                                   | 3 (17.7)                          | 3 (8.3)         | 0.0953  |
| CVAD                                      | 2 (10.5)                            | 1 (5.9)                           | 3 (8.3)         | 1       |
| PTE                                       | 0                                   | 1 (5.9)                           | 1 (2.8)         | 0.472   |
| Hyperlipidemia                            | 2 (10.5)                            | 1 (5.9)                           | 3 (8.3)         | 1       |
| Witnessed cardiac arrest                  | 13 (68.4)                           | 15 (88.2)                         | 28 (77.8)       | 0.236   |
| BLS (min)                                 | 16.1±14.4                           | 7.5±10.6                          | 12.0±13.3       | 0.05    |
| ACLS (min)                                | 8.2±8.0                             | 9.3±9.3                           | 8.7±8.5         | 0.71    |
| Targeted temperature management           | 6 (31.6)                            | 7 (41.2)                          | 13 (36.1)       | 0.55    |
| Continuous renal replacement therapy      | 5 (26.3)                            | 2 (11.8)                          | 7 (19.4)        | 0.408   |
| Extracorporeal membrane oxygenation       | 2 (10.5)                            | 0                                 | 2 (5.6)         | 0.487   |
| Coronary angiography                      | 1 (5.3)                             | 0                                 | 1 (2.8)         | 1       |
| Inotropic use                             | 17 (89.5)                           | 15 (88.2)                         | 32 (88.9)       | 1       |
| Muscle relaxant use                       | 8 (42.1)                            | 8 (47.1)                          | 16 (44.4)       | 0.765   |
| Initial laboratory value                  |                                     |                                   |                 |         |
| Hemoglobin (g/dl)                         | 10.9±2.9                            | 11.0±3.3                          | 10.9±3.0        | 0.923   |
| White blood cell (×10 <sup>9</sup> /L)    | 12.6±7.8                            | 13.2±6.2                          | 12.8±7.0        | 0.794   |
| AST (U/L)                                 | 562.5±1,367.5                       | 208.9±494.1                       | 395.5±1051.4    | 0.303   |
| ALT (U/L)                                 | 187.2±408.3                         | 122.6±261.6                       | 155.9±341.5     | 0.584   |
| BUN (mg/dl)                               | 29.2±18.1                           | 40.6±33.0                         | 34.6±26.5       | 0.219   |
| Creatinine (mg/dl)                        | 2.1±1.7                             | 2.5±2.5                           | 2.3±2.1         | 0.551   |
| C-reactive protein (mg/dl)                | 6.2±11.8                            | 4.0±7.4                           | 5.1±9.9         | 0.523   |
| Troponin I (pg/ml)                        | 85.7±173.8                          | 44.2±129.6                        | 66.1±153.8      | 0.427   |
| Feeding volume within initial 5 days (ml) | 122.1±372.4                         | 1,597.0±1,277.4                   | 818.6±1,194.1   | <0.001  |

Values are presented as mean±standard deviation or number (%).

CKD: Chronic kidney disease; ACS: acute coronary syndrome; COPD: chronic obstructive pulmonary disease; CVAD: cerebrovascular disease; PTE: pulmonary thromboembolism; BLS: basic life support; ACLS: advanced cardiovascular life support; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BUN: blood urea nitrogen.